OakChart

UroGen Pharma Ltd

URGNHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

26.10+0.78 (3.08%)
2026-11-12 05:51 CET
Market cap
1,280.15 USD m
Revenue, TTM
250.25 USD m
Net income, TTM
-65.75 USD m
Free cash flow, TTM
-136.57 USD m
EPS diluted, TTM
-1.33
P/E
-
Compare

Price

URGN against its 20, 50 and 200-day averages
2050200miss
20.0030.0040.0050.001.9M3.9MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26URGNclose 26.1020-day 31.9550-day 37.74200-day 31.6426.1052w high

48.6% under the 52-week high of 50.81 on 19 Aug 2026. 52-week low 16.50 on 30 Mar 2026. Last 15 sessions, 47.5% high to low

Volume 0.80× normal · the line is the 50-bar volume average

Profile

URGN
52-week range, 28% of the way up
16.5050.81

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

IndexRUT
Employees291
IPOMay 04, 2017
Beta1.68
ATR, 14d2.09
Rel volume0.80
Short float12.26%
Insider own15.09%
Inst own81.58%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.28B
Enterprise Value1.38B
Income-65.75M
Sales250.25M
Book/sh-2.55
Cash/sh1.87
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees291
IPOMay 04, 2017

Ratios

P/E-
Forward P/E10.46
PEG-
P/S5.12
P/B-
P/C13.93
P/FCF-
EV/EBITDA-
EV/Sales5.53
Quick Ratio3.06
Current Ratio3.40
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.33
EPS next Y2.50
EPS next Q0.39
EPS this Y88.45%
EPS next Y777.13%
EPS next 5Y-
EPS past 3/5Y12.81% 11.57%
Sales past 3/5Y19.49% 56.22%
EPS Y/Y TTM61.62%
Sales Y/Y TTM159.29%
EPS Q/Q95.84%
Sales Q/Q223.85%
EarningsNov 04 BMO
EPS/Sales Surpr.-128.38% -1.02%

Ownership

Insider Own15.09%
Insider Trans-1.34%
Inst Own81.58%
Inst Trans-0.70%
ROA-28.78%
ROE-
ROIC-95.42%
Gross Margin91.41%
Oper. Margin-12.36%
Profit Margin-26.27%
SMA20-18.32%
SMA50-30.84%
SMA200-17.50%
Trades-

Technical

Shs Outstand49.03M
Shs Float41.65M
Short Float12.26%
Short Ratio5.01
Short Interest5.11M
52W High50.81 -48.63%
52W Low16.50 58.18%
Volatility8.33% 6.68%
ATR (14)2.09
RSI (14)27.80
Beta1.68
Rel Volume0.80
Avg Volume1.02M
Volume818,375

Performance

Perf Week-9.19%
Perf Month-31.78%
Perf Quarter-45.76%
Perf Half Y-15.64%
Perf YTD11.44%
Perf Year10.45%
Perf 3Y127.75%
Perf 5Y38.76%
Perf 10Y-
Recom1.00
Target Price60.71
Prev Close25.32
Price26.10
Change %3.08%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
May 11, 2026ResumedLLadenburg ThalmannBuy$43+64.8%
Apr 10, 2026InitiatedJJefferiesBuy$40+53.3%
Aug 19, 2025InitiatedPPiper SandlerOverweight$36+37.9%
Jun 16, 2025UpgradeHH.C. WainwrightNeutral → Buy$50+91.6%
May 22, 2025DowngradeHH.C. WainwrightBuy → Neutral
Apr 16, 2025InitiatedBScotiabankSector Outperform$23-11.9%
Feb 19, 2025ResumedLLadenburg ThalmannBuy$31+18.8%
Aug 22, 2024InitiatedGGuggenheimBuy$40+53.3%
Feb 08, 2023DowngradeJJefferiesBuy → Hold$35 → $10-61.7%
Apr 27, 2022InitiatedBBerenbergBuy$20-23.4%

Peers

Mkt cap
TickerCompanyMkt cap
CGONCg Oncology Inc6.49B
ENGNenGene Therapeutics Inc120.63M
RLMDRelmada Therapeutics Inc472.55M
TARAProtara Therapeutics Inc161.32M
JANXJanux Therapeutics Inc758.06M
TLXTelix Pharmaceuticals Ltd ADR3.31B
AKTSAktis Oncology Inc947.76M
EXELExelixis Inc17.25B
PBYIPuma Biotechnology Inc417.72M
ARTVArtiva Biotherapeutics Inc201.19M

Insider trading

latest 14 of 21
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Degnan ChrisChief Financial OfficerOct 08 '26Sale36.692,20280,7914,561Oct 09 12:57 PM
Christopher DegnanOfficerOct 08 '26Proposed Sale40.702,20289,621Oct 09 06:23 AM
Schoenberg MarkChief Medical OfficerSep 08 '26Sale42.9287137,38359,882Sep 09 02:37 PM
Smith Jason DrewGeneral CounselSep 08 '26Sale42.541,51964,61853,141Sep 09 02:35 PM
Mark SchoenbergOfficerSep 08 '26Proposed Sale44.0987138,402Sep 09 07:34 AM
Jason SmithOfficerSep 08 '26Proposed Sale44.091,51966,973Sep 09 07:34 AM
Schoenberg MarkChief Medical OfficerAug 20 '26Sale47.0560,6772,854,85359,086Aug 24 05:03 PM
Schoenberg MarkOfficerAug 20 '26Proposed Sale47.6760,6772,892,242Aug 20 01:24 PM
Schoenberg MarkChief Medical OfficerJul 09 '26Sale40.0010,000400,000119,763Jul 10 02:17 PM
Schoenberg MarkOfficerJul 09 '26Proposed Sale40.0010,000400,008Jul 09 04:19 PM
Schoenberg MarkChief Medical OfficerJun 22 '26Sale35.0110,000350,100129,763Jun 24 10:22 AM
Schoenberg MarkOfficerJun 22 '26Proposed Sale35.0110,000350,143Jun 22 03:53 PM
Schoenberg MarkChief Medical OfficerJun 08 '26Sale27.305,222142,561139,763Jun 09 01:59 PM
Schoenberg MarkOfficerJun 08 '26Proposed Sale26.855,222140,211Jun 09 07:50 AM

Held by

AUM
TickerCompanyAUM
IWMiShares Russell 2000 Index FundAUM: 77.38B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
SPDWState Street SPDR Portfolio Developed World ex-US ETFAUM: 41.64B
VHTVanguard Health Care ETFAUM: 21.51B
IWCiShares Micro-Cap ETFAUM: 1.22B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
IWNiShares Russell 2000 Value ETFAUM: 14.10B

News

latest 14 of 200
  • UroGen Misses EPS Target But Edges Toward Breakeven As ZUSDURI Scales; JELMYTO Cut And A Normalizing Launch Curve Complicate The Story (Earnings Whispers) -16.45% -10.47%
  • UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights (GlobeNewswire)
  • UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference (GlobeNewswire)
  • UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer (GlobeNewswire) +5.01%
  • UroGen's Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer (GlobeNewswire)
  • UroGen's Zysturi Ramp Faces A Summer Test As Wall Street Pencils In A Profit (Earnings Whispers)
  • UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026 (GlobeNewswire)
  • UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC (GlobeNewswire)
  • Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress (Barrons.com)
  • UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • UroGen Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
  • UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline (GlobeNewswire) -6.94%
  • UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC (GlobeNewswire)
  • UroGen Pharma Ltd (URGN) (Q2 2026) Earnings Call Highlights: Cysview Revenue Surges 73% as Net ... (GuruFocus.com) +16.31%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-0.0300.106-0.03089.0089.927
2026Q22026-08-05-0.280-0.265-0.28572.4663.558
2026Q12026-05-06-0.470-0.482-0.47050.9644.838
2025Q42026-03-02-0.540-0.502-0.54537.8439.918
2025Q32025-11-06-0.690-0.692-0.69427.4832.478
2025Q22025-08-07-1.050-0.865-1.04624.2223.308
2025Q12025-05-12-0.920-0.799-0.92520.2522.798
2024Q42025-03-10-0.800-0.720-0.79824.5725.637
2024Q32024-11-06-0.550-0.817-0.54925.2024.207
2024Q22024-08-13-0.910-0.832-0.90721.8523.975
2024Q12024-05-13-0.970-0.867-0.96718.7821.395
2023Q42024-03-14-0.720-0.680-0.72023.5322.575
2023Q32023-11-14-0.680-0.846-0.67720.8520.035
2023Q22023-08-10-1.030-1.136-1.02921.1420.125
2023Q12023-05-11-1.300-1.330-1.29817.1917.116
2022Q42023-03-16-1.220-1.073-1.22418.0918.516

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-5.120-4.951-5.1220.020.02
2020FY-5.900-5.921-5.89911.8011.51
2021FY-4.960-4.822-4.95948.0448.11
2022FY-4.790-4.518-4.81464.3664.78
2023FY-3.550-3.564-3.54682.7181.75
2024FY-2.960-3.127-2.95990.4091.00
2025FY-3.190-3.197-3.190109.8111.88
2026FY--0.369--319.5
2027FY-2.496--534.85
2028FY-5.802--761.08
2029FY-6.116--827.01
2030FY-7.760--997.89

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-04724107.0995.14114
2026Q4S2026-10-29701108.5994.51118.4
2026Q4S2026-10-27801107.2994.51118.4
2026Q4S2026-10-19800108.2294.51118.4
2026Q4S2026-09-08880108.2294.51118.4
2026Q4S2026-08-05880108.2394.51118.43
2026Q4S2026-07-2284086.3676.12103.5
2026Q4S2026-07-2084186.3676.12103.5
2026Q4S2026-07-1785286.3276.12103.5
2026Q4S2026-07-1585284.5676.12103.5
2026Q4S2026-07-1485284.1976.10100.5
2026Q4S2026-07-0884382.8271.59100.5
2026Q4S2026-06-3084382.8271.59100.5
2026Q4S2026-05-2683481.0268.40100.5

Estimate history

EPS, annual-2.14-4.802-5.122-5.899-4.959-4.814-3.546-2.959-3.19-1.3288
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.549-0.798-0.925-1.046-0.694-0.545-0.47-0.285-0.029
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual8.1581.1280.01811.79948.04264.35782.71390.398109.788250.25
Period201720182019202020212022202320242025TTM
Sales, quarterly25.20424.56520.25424.21527.48237.83750.95972.45689.001
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual13.75116.21521.02622.16822.46323.1332.4942.23248.3549.029
Period201720182019202020212022202320242025MRQ
Shares, quarterly42.19142.23246.10246.19946.78148.3548.70848.8749.029
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue250.25109.7990.4082.7164.3648.0411.800.021.13
Cost of Goods Sold Incl. D&A21.5012.458.889.367.655.163.05-1.80
Gross Profit228.7597.3481.5273.3556.7042.888.75--0.68
Selling, General and Administrative Excl. Other259.69222.20178.30138.89135.74135.18135.49108.1776.51
Research and Development73.2167.1157.1545.6152.9147.6445.2749.3036.93
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-30.94-124.86-96.78-65.54-79.04-92.29-126.74-109.48-77.18
Interest Expense35.9333.8535.9336.2730.0017.440.360.280.00
Unusual Expense0.000.000.000.000.000.000.00-0.00
Net Income Before Taxes-64.15-153.42-124.04-98.32-108.03-109.37-125.11-105.15-75.53
Income Taxes1.600.082.833.921.761.453.370.000.13
Consolidated Net Income-65.75-153.49-126.87-102.24-109.78-110.82-128.48-105.15-75.66
Net Income From Continuing Operations-65.75-153.49-126.87-102.24-109.78-110.82-128.48-105.15-75.66
Net Income-65.75-153.49-126.87-102.24-109.78-110.82-128.48-105.15-75.66
EPS (Recurring)-1.30-3.19-2.96-3.55-4.81-4.96-5.90-5.12-4.80
EPS (Basic, Before Extraordinaries)-1.33-3.19-2.96-3.55-4.81-4.96-5.90-5.12-4.80
EPS (Diluted)-1.33-3.19-2.96-3.55-4.81-4.96-5.90-5.12-4.80
EBITDA-28.25-122.45-95.60-63.83-77.22-90.52-124.69-108.15-76.76
Non-Operating Income (Expense)2.725.308.673.481.010.371.994.621.65
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense15.279.4510.367.388.1517.8021.5823.0723.29
Price To Sales Ratio8.2110.265.055.233.144.4233.2638,057.98601.40
Gross Margin91.4188.6690.1888.6888.1189.2774.12--59.84
Operating Margin-12.36-113.73-107.06-79.23-122.82-192.11-1,074.15-608,211.11-6,842.20
Net Margin-26.27-139.81-140.35-123.61-170.58-230.67-1,088.94-584,144.44-6,707.18
Shares Outstanding49.0348.3542.2332.4923.1322.4622.1721.0316.21
Market Capitalization1,280.151,280.15449.42462.11204.81213.22398.12700.10693.35

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue89.0072.4650.9637.8427.4824.2120.2524.57
Cost of Goods Sold Incl. D&A7.506.574.143.293.283.552.332.47
Gross Profit81.5065.8846.8234.5524.2020.6617.9222.09
Selling, General and Administrative Excl. Other73.1765.7767.0853.6651.5962.1154.8449.75
Research and Development25.9617.3415.6014.3114.0118.9119.8714.89
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income8.330.11-20.26-19.11-27.39-41.45-36.91-27.66
Interest Expense9.389.438.698.437.998.788.659.96
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-0.45-8.72-28.35-26.64-34.40-48.93-43.45-34.86
Income Taxes1.025.63-4.77-0.28-1.051.020.392.65
Consolidated Net Income-1.46-14.35-23.57-26.36-33.35-49.94-43.84-37.51
Net Income From Continuing Operations-1.46-14.35-23.57-26.36-33.35-49.94-43.84-37.51
Net Income-1.46-14.35-23.57-26.36-33.35-49.94-43.84-37.51
EPS (Recurring)-0.03-0.28-0.47-0.55-0.69-1.05-0.92-0.80
EPS (Basic, Before Extraordinaries)-0.03-0.28-0.47-0.55-0.69-1.05-0.92-0.80
EPS (Diluted)-0.03-0.28-0.47-0.55-0.69-1.05-0.92-0.80
EBITDA9.020.78-19.61-18.44-26.75-40.85-36.42-27.35
Non-Operating Income (Expense)0.610.600.610.900.981.302.112.75
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense4.934.213.662.472.392.162.422.61
Price To Sales Ratio8.219.826.4210.319.936.945.715.54
Gross Margin91.5790.9391.8891.3188.0785.3488.5089.94
Operating Margin9.360.15-39.76-50.52-99.65-171.17-182.26-112.59
Net Margin-1.64-19.81-46.26-69.68-121.34-206.24-216.47-152.71
Shares Outstanding49.0348.8748.7148.3546.7846.2046.1042.23
Market Capitalization1,280.151,792.96875.311,096.26922.97631.67509.80449.42

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments121.81237.76137.79100.7890.36103.24147.60101.5773.20
Short Term Receivables33.0820.3015.4412.7011.727.050.000.00-
Inventories16.469.235.674.334.831.960.000.000.32
Other Current Assets14.678.8510.2811.107.483.361.030.670.96
Total Current Assets186.02276.13169.19128.91114.39115.62148.63102.2474.47
Net Property, Plant & Equipment9.093.792.363.753.154.200.980.950.81
Total Investments and Advances0.185.204.730.220.902.1248.780.050.03
Long-Term Note Receivable------3.73--
Intangible Assets--------0.00
Other Assets5.160.592.042.741.310.070.260.320.24
Total Assets200.46285.71178.31135.62119.75122.00202.39103.5675.55
Short Term Debt Incl. Current Port. of LT Debt1.751.530.820.943.331.860.000.000.00
Accounts Payable12.1410.936.515.535.793.274.694.274.43
Other Current Liabilities32.5333.4923.8817.4513.2616.3114.799.192.60
Total Current Liabilities46.4245.9531.2123.9222.3821.4419.4813.467.04
Long Term Debt128.33123.3999.3999.120.401.502.600.000.00
Provision for Risks Charges3.903.793.193.022.842.720.000.00-
Other Liabilities127.28121.39109.7298.9285.710.000.000.000.00
Total Liabilities305.93294.51243.52224.98111.3325.6522.0913.467.04
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity-105.47-8.80-65.21-89.368.4196.36180.3090.0968.52
Total Shareholders Equity-105.47-8.80-65.21-89.368.4196.36180.3090.0968.52
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity-105.47-8.80-65.21-89.368.4196.36180.3090.0968.52
Total Liabilities & Stockholders Equity200.46285.71178.31135.62119.75122.00202.39103.5675.55
Book Value Per Share-2.18-0.21-2.01-3.860.374.358.585.564.98
Tangible Book Value Per Share-2.18-0.21-2.01-3.860.374.358.585.564.98
Full-Time Employees2912352012001951871737042
Price to Book Ratio-10.2217.61-11.02-3.2325.394.153.897.756.43
Return on Assets-63.14-54.68-65.14-85.98-91.68-79.22-68.73-84.48-40.57
Return on Equity-----211.55-92.88-77.77-95.40-47.16
Return on Invested Capital-671.51-110.73-299.11-1,124.60-1,257.75-131.30-57.49-83.98-29.19
Quick Ratio3.655.815.245.214.905.307.637.5910.54
Current Ratio4.016.015.425.395.115.397.637.5910.59

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-69.40-153.49-126.87-102.24-109.78-110.82-128.48-105.15-75.66
Depreciation2.772.411.191.711.821.772.041.320.42
Other Funds (Non Cash)25.1016.5523.9920.8326.7137.2626.9228.4930.74
Funds from Operations-41.53-134.53-101.70-79.71-81.25-71.79-99.52-75.34-44.50
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-94.84-27.914.933.34-6.31-13.11-6.374.327.16
Income Taxes Payable----0.180.133.37--
Cash from Operating Activities-136.37-162.44-96.77-76.38-87.56-84.89-105.89-71.02-37.33
Capital Expenditures-0.21-0.29-0.30-0.19-0.25-0.75-1.22-0.33-0.56
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments30.9561.85-20.32-0.761.314.8294.45-145.2735.85
Purchase of Investments-30.61-77.40-128.02-49.83-63.01-51.90-29.69-197.86-0.05
Sale Or Maturity of Investments61.56139.25107.7149.0764.3256.72124.1452.5935.90
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities30.7561.56-20.61-0.951.064.0793.24-145.5935.29
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock38.7841.77170.13116.931.35-0.0816.53165.2566.42
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock38.7841.77170.13116.931.35-0.0816.53165.2566.42
Proceedsfrom Stock Options33.8839.80151.1767.36-0.16-0.1415.79161.5964.02
Issuance or Reduction of Debt, Net62.29-1.8524.490.0095.780.000.000.000.00
Change in Long Term Debt62.29-1.8624.490.0095.780.000.000.000.00
Issuance of Long Term Debt65.580.0024.490.0095.780.000.000.000.00
Reduction of Long Term Debt-3.30-1.860.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.0072.400.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities101.0739.92194.62116.9397.1372.3216.53165.2566.42
Net Change in Cash-4.55-60.9777.2439.6010.64-8.503.88-51.3664.37
Free Cash Flow-136.57-162.73-97.06-76.57-87.81-85.64-107.10-71.34-37.89
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments91.88109.30141.60121.81128.38158.04
Short Term Receivables117.2888.7655.4133.0819.7019.65
Inventories25.1524.5920.9216.468.347.13
Other Current Assets17.5812.7819.5314.6712.1212.05
Total Current Assets251.90235.43237.46186.02168.55196.87
Net Property, Plant & Equipment7.948.228.569.099.186.24
Total Investments and Advances0.180.180.180.180.564.81
Other Assets11.868.767.495.166.760.80
Total Assets271.87252.59253.69200.46185.05208.72
Short Term Debt Incl. Current Port. of LT Debt2.162.101.921.751.591.55
Accounts Payable17.2615.4717.2112.1410.2813.56
Other Current Liabilities54.6144.3531.5132.5330.3832.44
Total Current Liabilities74.0361.9150.6346.4242.2447.55
Long Term Debt194.12194.03195.18128.33128.35125.92
Provision for Risks Charges3.903.903.903.903.793.79
Other Liabilities125.03125.14128.23127.28126.07124.83
Total Liabilities397.09384.99377.94305.93300.45302.09
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-125.22-132.40-124.25-105.47-115.41-93.38
Total Shareholders Equity-125.22-132.40-124.25-105.47-115.41-93.38
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-125.22-132.40-124.25-105.47-115.41-93.38
Total Liabilities & Stockholders Equity271.87252.59253.69200.46185.05208.72
Book Value Per Share-2.55-2.71-2.55-2.18-2.47-2.02
Tangible Book Value Per Share-2.55-2.71-2.55-2.18-2.47-2.02
Full-Time Employees---291--
Price to Book Ratio-10.22-14.43-8.24-9.49-9.87-13.59
Return on Assets-28.78-42.33-53.15-63.14-67.62-63.18
Return on Invested Capital-2.12-23.28-33.24-115.34-257.63-153.45
Quick Ratio3.063.414.283.653.793.99
Current Ratio3.403.804.694.013.994.14

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-0.63-15.32-23.57-29.87-38.75-50.33
Depreciation0.670.700.650.750.710.60
Other Funds (Non Cash)6.965.587.694.874.464.31
Funds from Operations7.00-9.04-15.24-24.25-33.58-45.42
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-20.52-25.98-30.08-18.26-14.015.25
Cash from Operating Activities-13.53-35.02-45.32-42.51-47.59-40.17
Capital Expenditures-0.07-0.06-0.05-0.02-0.10-0.14
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments20.411.25-20.6329.9333.0328.56
Purchase of Investments-3.47-0.64-24.78-1.72-11.94-2.07
Sale Or Maturity of Investments23.881.884.1531.6544.9730.63
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities20.341.19-20.6929.9032.9328.42
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock2.380.910.1835.318.660.30
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock2.380.910.1835.318.660.30
Proceedsfrom Stock Options0.000.000.0033.888.33-0.00
Issuance or Reduction of Debt, Net64.98-0.41-0.32-1.970.000.00
Change in Long Term Debt64.98-0.41-0.32-1.970.000.00
Issuance of Long Term Debt65.580.000.000.000.000.00
Reduction of Long Term Debt-0.60-0.41-0.32-1.970.000.00
Net Financing Active Other Cash Flow-67.021.6865.350.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.342.1965.2033.348.660.30
Net Change in Cash7.15-31.64-0.8020.74-6.00-11.45
Free Cash Flow-13.60-35.08-45.37-42.53-47.69-40.31

Revenue breakdown

Jelmyto2024: 90.40M 2025: 93.99M
Zusduri2025: 15.80M
Israel2024: 90.40M 2025: 109.79M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3012.26%5.1M41.7M945.64K
2026-10-1513.51%5.6M41.5M890.76K
2026-09-3018.71%7.8M41.5M837.41K
2026-09-1515.05%6.2M41.5M817.98K
2026-08-3115.05%6.2M41.5M812.80K
2026-08-1412.36%5.1M41.4M767.35K
2026-07-3111.28%4.6M40.7M787.05K
2026-07-1514.03%5.7M40.5M810.98K
2026-06-3016.14%6.2M38.5M788.80K
2026-06-1517.03%6.6M38.5M795.46K
2026-05-2917.98%6.9M38.5M868.90K
2026-05-1517.59%6.8M38.5M891.12K
2026-04-3018.77%7.2M38.6M797.52K
2026-04-1520.31%7.8M38.5M778.70K
2026-03-3120.91%8.3M39.9M783.48K
2026-03-1321.61%8.6M39.9M795.21K
2026-02-2720.08%8.0M39.9M751.85K
2026-02-1324.32%9.3M38.4M809.20K
2026-01-3026.61%10.3M38.7M973.32K
2026-01-1527.31%10.6M38.7M990.72K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call5.0018.7023.500.0014.3250.000.000.971-0.1360.003
call10.0013.5018.2030.007.7041.000.000.943-0.1400.005
call11.0012.5016.900.005.9600.000.000.937-0.1390.005
call12.0011.5016.300.006.4730.000.000.930-0.1370.005
call13.0010.5015.200.005.9500.000.000.923-0.1350.006
call14.009.9014.500.005.8290.000.000.915-0.1330.006
call15.009.0013.400.005.2540.000.000.907-0.1300.007
call16.008.0012.100.004.5130.000.000.877-0.1680.008
call17.007.0010.509.063.5101.000.000.853-0.1910.009
call18.006.009.608.123.2891.000.000.839-0.1850.010
call19.005.009.600.003.7010.000.000.822-0.1780.011
call20.004.008.605.103.5264.000.000.804-0.1700.011
call21.003.007.500.002.7130.000.000.780-0.1650.012
call22.002.507.200.003.3040.000.000.748-0.1660.013
call23.002.255.500.002.3270.000.000.722-0.1430.014
call24.001.003.600.001.5420.000.000.677-0.1380.015
call25.000.804.901.381.90316.000.000.619-0.1370.015
call26.000.202.852.101.7300.000.000.567-0.1780.016
call27.001.502.001.451.5913,3475450.516-0.1780.016
call28.000.201.950.001.6970.000.000.455-0.1620.016
call29.000.054.901.751.9022710.000.419-0.1720.016
call30.000.001.000.601.4495600.000.301-0.1160.014
call31.000.001.403.501.5792.000.000.283-0.1240.014
call32.000.001.100.501.7249.000.000.267-0.1310.013
call33.000.001.150.051.8591.000.000.254-0.1370.013
call34.000.004.900.351.9461280.000.236-0.1380.013
call35.000.002.350.402.0662170.000.227-0.1440.012
call36.000.004.900.372.17932.000.000.219-0.1480.012
call37.000.001.501.402.32914.000.000.218-0.1580.012
call38.000.004.901.652.3895.000.000.206-0.1570.012
call39.000.001.551.162.53211.000.000.206-0.1660.012
call40.000.000.750.052.3966280.000.169-0.1390.010
call41.000.004.900.872.4845.000.000.165-0.1420.010
call42.000.004.900.502.5685.000.000.161-0.1450.010
call43.000.004.900.502.64928.000.000.158-0.1470.010
call44.000.004.900.002.7280.000.000.155-0.1500.010
call45.000.004.900.382.80449.000.000.152-0.1520.010
call46.000.001.600.512.87820.000.000.149-0.1540.009
call47.000.001.550.002.9500.000.000.147-0.1560.009
call48.000.004.900.903.0190.000.000.145-0.1580.009
call49.000.001.150.213.0861.000.000.142-0.1600.009
call50.000.000.050.011.9255264.000.019-0.0210.002
call55.000.002.000.102.11315.000.000.018-0.0210.002
call60.000.004.900.102.3144570.000.017-0.0220.002
call65.000.001.601.302.49518.000.000.016-0.0230.002
call70.000.004.900.002.6601.000.000.015-0.0230.002
call75.000.004.900.002.8120.000.000.014-0.0230.001
put5.000.004.900.008.8450.000.00-0.029-0.1360.003
put10.000.004.900.005.2810.000.00-0.057-0.1390.005
put11.000.004.900.004.8250.000.00-0.063-0.1370.005
put12.000.004.900.004.4120.000.00-0.070-0.1360.005
put13.000.004.900.004.0350.000.00-0.077-0.1340.006
put14.000.004.900.503.6860.000.00-0.085-0.1310.006
put15.000.000.751.103.3622.000.00-0.093-0.1280.007
put16.000.001.150.003.5720.000.00-0.123-0.1670.008
put17.000.004.900.003.0190.000.00-0.125-0.1420.008
put18.000.004.901.653.2571.000.00-0.161-0.1830.010
put19.000.004.902.002.9471.000.00-0.178-0.1760.011
put20.000.001.451.452.6492.000.00-0.196-0.1680.011
put21.000.004.900.902.5271.000.00-0.226-0.1740.012
put22.000.004.901.052.2361.000.00-0.252-0.1630.013
put23.000.004.903.401.9491.000.00-0.284-0.1510.014
put24.000.001.551.201.6626.000.00-0.323-0.1350.015
put25.000.802.701.201.40211.0030.00-0.381-0.1340.015
put26.000.303.202.052.1531.000.00-0.433-0.1750.016
put27.000.604.902.302.5978.000.00-0.484-0.1750.016
put28.001.104.701.762.2102.000.00-0.545-0.1590.016
put29.002.306.504.092.9131.000.00-0.581-0.1680.016
put30.002.957.001.802.79629.000.00-0.696-0.1120.014
put31.004.708.003.192.97413.000.00-0.717-0.1200.014
put32.004.508.207.152.6325881.00-0.733-0.1270.013
put33.006.209.502.852.9775.000.00-0.746-0.1340.013
put34.006.5010.504.603.1212.000.00-0.764-0.1350.013
put35.007.1011.5010.083.2570.000.00-0.767-0.1450.012
put36.008.1012.501.523.3862.000.00-0.775-0.1500.012
put37.009.7013.502.673.50910.000.00-0.788-0.1490.012
put38.0010.0014.505.003.6270.000.00-0.788-0.1580.012
put39.0011.8015.500.003.7390.000.00-0.794-0.1620.012
put40.0012.0016.5012.003.8471230.00-0.831-0.1350.010
put41.0013.0017.507.103.9501.000.00-0.835-0.1380.010
put42.0014.0018.509.004.0491.000.00-0.839-0.1400.010
put43.0015.0019.505.104.1450.000.00-0.842-0.1430.010
put44.0016.0020.500.004.2380.000.00-0.845-0.1450.010
put45.0017.0021.506.284.3260.000.00-0.848-0.1470.010
put46.0018.7022.5016.604.4130.000.00-0.851-0.1490.009
put47.0019.0023.500.004.4960.000.00-0.853-0.1510.009
put48.0020.7024.500.004.5770.000.00-0.855-0.1530.009
put49.0021.0025.500.004.6550.000.00-0.858-0.1550.009
put50.0022.0026.5015.614.7310.000.00-0.980-0.0150.002
put55.0027.0031.500.005.0820.000.00-0.982-0.0150.002
put60.0032.8036.500.005.3910.000.00-0.983-0.0150.002
put65.0037.0041.500.005.6670.000.00-0.984-0.0150.002
put70.0042.0046.500.005.9160.000.00-0.985-0.0150.002
put75.0047.0051.500.006.1430.000.00-0.986-0.0150.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-04S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-10-27SCHEDULE 13G/ASEC
2026-10-09144Filing for proposed sale of securities under Rule 144.SEC
2026-10-094Statement of changes in beneficial ownership of securities2026-10-08SEC
2026-09-09144Filing for proposed sale of securities under Rule 144.SEC
2026-09-09144Filing for proposed sale of securities under Rule 144.SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-07SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-07SEC
2026-08-284Statement of changes in beneficial ownership of securities2026-08-26SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-20SEC
2026-08-208-KCurrent report2026-08-18SEC
2026-08-20144Filing for proposed sale of securities under Rule 144.SEC
2026-08-12SCHEDULE 13G/ASEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-09144Filing for proposed sale of securities under Rule 144.SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-238-KCurrent report2026-06-22SEC
2026-06-22144Filing for proposed sale of securities under Rule 144.SEC
2026-06-09144Filing for proposed sale of securities under Rule 144.SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-08SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100080.79K1
2026-0900102.00K2
2026-08002.85M1
2026-0700400.00K1
2026-0600492.66K2
2026-0500300.00K1
2026-040000
2026-030000
2026-0200292.44K2
2026-010000
2025-120000
2025-1100250.00K1

Institutional holders

Manager% owned
RTW INVESTMENTS, LP9.33%
BlackRock, Inc.6.57%
MORGAN STANLEY5.29%
Kynam Capital Management, LP5.00%
Jefferies Financial Group Inc.4.50%
SG Americas Securities, LLC4.21%
AMERICAN CENTURY COMPANIES INC3.46%
ACORN CAPITAL ADVISORS, LLC3.43%
Point72 Asset Management, L.P.3.13%
FRONTIER CAPITAL MANAGEMENT CO LLC3.10%

Funds

Fund% owned
VANGUARD TOTAL INTERNATIONAL BOND II INDEX FUND269.19%
VANGUARD TOTAL INTERNATIONAL BOND INDEX FUND189.81%
State Street(R) SPDR(R) Bloomberg Emerging Markets Local Bond ETF38.61%
iShares International Treasury Bond ETF20.82%
iShares Core International Aggregate Bond ETF17.00%
State Street(R) SPDR(R) FTSE International Government Inflation-Protected Bond ETF8.55%
State Street(R) SPDR(R) Bloomberg International Treasury Bond ETF7.21%
VANGUARD GLOBAL EX-U.S. REAL ESTATE INDEX FUND6.36%
iShares Global Government Bond USD Hedged Active ETF5.70%
iShares Russell 2000 ETF2.27%

OakChart. URGN. Cached 15 minutes.